Position in QURE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,909,000
New position
Shares Held
150,000
first reported quarter
Ownership
0.238%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
#66
of 255 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Casdin Capital, LLC holds $1,258,350,419 across 31 Biotechnology names. QURE ranks #19 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,577,333 | $482,682,924 | |
| 2 | RLAY |
Relay Therapeutics, Inc.
|
16,035,240 | $300,019,340 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
1,175,000 | $63,062,250 | |
| 4 | DNLI |
Denali Therapeutics Inc.
|
2,045,000 | $52,597,400 | |
| 5 | NGNE |
Neurogene Inc.
|
1,545,361 | $48,601,603 | |
| 6 | BEAM |
Beam Therapeutics Inc.
|
1,350,000 | $46,332,000 | |
| 7 | SRRK |
Scholar Rock Holding Corp
|
665,000 | $36,575,000 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
843,857 | $25,180,692 |
All Filings in QURE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,909,000 | 150,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||